Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.38 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.38 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 10/20 | 0.36 |
| ▸ | CTSL | P07711 | 5/20 | 0.36 |
| ▸ | CTSK | P43235 | 4/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13249274 | 0.94 | CYP3A4 (0.38) | CYP3A4CYP3A5CYP3A7CYP3A43CTSB | |
| SCHEMBL14628793 | 0.93 | CYP3A4 (0.38) | CYP3A4CYP3A5CYP3A7CYP3A43CTSB | |
| SCHEMBL14279171 | 0.93 | CTSB (0.38) | CYP3A4CYP3A5CYP3A7CYP3A43CTSB | |
| SCHEMBL8251122 | 0.91 | CTSB (0.41) | CYP3A4CYP3A5CYP3A7CYP3A43CTSB | |
| SCHEMBL13225091 | 0.90 | CTSB (0.45) | CYP3A4CYP3A5CYP3A7CYP3A43CTSB | |
| SCHEMBL13249154 | 0.89 | CYP3A4 (0.33) | CYP3A4CYP3A5CYP3A7CYP3A43 | |
| SCHEMBL13225078 | 0.89 | CTSB (0.38) | CYP3A4CYP3A5CYP3A7CYP3A43CTSB | |
| SCHEMBL13249269 | 0.87 | CTSB (0.37) | CYP3A4CYP3A5CYP3A7CYP3A43CTSB | |
| SCHEMBL13249216 | 0.85 | CTSV (0.41) | CTSBCTSLCTSK | |
| SCHEMBL16301701 | 0.85 | CYP3A4 (0.40) | CYP3A4CYP3A5CYP3A7CYP3A43CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | IFNAR1, IFNG, IRF3 | CYP3A4 157/4885CYP3A5 145/4885CYP3A7 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.